HeartBeam (BEAT) Stock Price, News & Analysis

Company Overview

HeartBeam, Inc. is a medical technology company developing portable cardiac-monitoring solutions designed to help detect and evaluate heart conditions outside traditional clinical settings. Its technology is intended to provide patients and healthcare professionals with more comprehensive electrocardiogram (ECG) information than conventional single-lead wearable devices.

The company’s primary product is the HeartBeam AIMIGo system, a compact, cable-free device that records a three-dimensional, vector-based ECG. Used with a mobile application, the system is designed to capture cardiac data when symptoms occur and share the resulting information with healthcare providers for review. HeartBeam’s platform is focused particularly on the remote assessment of possible cardiac events, including symptoms that may be associated with heart attacks.

HeartBeam’s technology is being developed for use in the United States and other healthcare markets where remote cardiac monitoring and digital health services are expanding. The company is headquartered in Santa Clara, California, and has focused its business on developing and commercializing its proprietary ECG platform rather than operating as a diversified medical-device manufacturer.

Key Stats

• Today's Range: $0.40 to $0.44
• 50-Day Range: $0.36 to $0.65
• 52-Week Range: $0.36 to $4.00
• Volume: 1.21 million shs
• Average Volume: 22.18 million shs
• Market Capitalization: $24.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Moderate Buy

HeartBeam Stock Analysis - MarketRank™

HeartBeam scored higher than 44% of companies evaluated by MarketBeat, and ranked 636th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

HeartBeam has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 1 strong buy rating, 4 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

HeartBeam has a consensus price target of $4.00, representing about 827.0% upside from its current price of $0.43.

Amount of Analyst Coverage

HeartBeam has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for HeartBeam are expected to grow in the coming year, from ($0.37) to ($0.24) per share.

Price to Book Value per Share Ratio

HeartBeam has a P/B Ratio of 7.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.39% of the float of HeartBeam has been sold short.

Short Interest Ratio / Days to Cover

HeartBeam has a short interest ratio ("days to cover") of 6.22.

Change versus previous month

Short interest in HeartBeam has recently increased by 17.39%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HeartBeam does not currently pay a dividend.

Dividend Growth

HeartBeam does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.87

News Sentiment

HeartBeam has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for HeartBeam this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for BEAT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added HeartBeam to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HeartBeam insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.95% of the stock of HeartBeam is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

7.77% of the stock of HeartBeam is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:BEAT
• CIK: 1574774
• Web: www.gobio.com
• Phone: 610-729-7000
• Fax: N/A
• Employees: 1,700
• Year Founded: N/A

Price Target and Rating

• Average Price Target for HeartBeam: $4.00
• High Price Target: $5.50
• Low Price Target: $2.00
• Potential Upside/Downside: +827.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.01 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -686.78%
• Return on Assets: -348.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.66
• Quick Ratio: 3.61

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.06 per share
• Price / Book: 7.19

Miscellaneous

• Outstanding Shares: 56,350,000
• Free Float: 46,234,000
• Market Cap: $24.32 million
• Optionable: Not Optionable
• Beta: -0.76